Omega-3 处方药市场、机会、成长动力、产业趋势分析与预测，2024-2032 年

全球 Omega-3 处方药市场价值约 14 亿美元。预测显示，从2024 年到2032 年，复合年增长率为8.2%。而成，主要用于治疗或管理心血管等疾病疾病、代谢障碍、某些发炎或神经系统问题。

心血管疾病盛行率的上昇在很大程度上推动了市场的成长。世界心臟联盟 (WHF) 的一份报告强调，2021 年全球心血管疾病 (CVD) 死亡人数达到 2050 万人。 CVD 成为 2021 年全球主要死因，其中 80% 的死亡发生在 CVD 上，令人震惊低收入和中等收入国家(LMIC)。这些统计数据强调了对 omega-3 处方药等有效治疗方法的迫切需求，以管理心血管疾病并改善全球健康。

研究与发展 (R&D) 的进步正在放大 omega-3 处方药的治疗潜力并扩大其应用。纯化和配方技术的创新正在生产高浓度的 omega-3 製剂，具有增强的生物利用度和功效。这些进步旨在充分利用二十碳五烯酸 (EPA) 和二十二碳六烯酸 (DHA) 的治疗功效，同时减少潜在的副作用。此外，正在进行的研究正在深入研究 omega-3 处方药的其他治疗途径，其范围不仅限于心血管健康。探索领域包括神经系统疾病、代谢障碍和发炎性疾病，以及评估 omega-3 治疗阿兹海默症、类风湿性关节炎和糖尿病的临床试验。

全球 Omega-3 处方药产业根据药物类型、应用、配销通路和地区进行分类。

市面上将药物类型分为vascepa、lovaza等。预测显示，到 2032 年，Vascepa 市场的销售额将达到 13 亿美元。 Vascepa 是一种高度浓缩和精製的配方，含有纯二十碳五烯酸 (EPA)。这种高纯度保证了 EPA 的有效剂量，不含纯度较低的 omega-3 补充剂中的常见污染物，从而增强了其功效。临床证据强调了Vascepa 的实力：正如REDUCE-IT 试验等研究所强调的那样，它不仅可以有效抑制三酸甘油酯水平升高（主要心血管疾病危险因子），而且还可以显着降低主要心血管事件的风险。

到 2032 年，美国 omega-3 处方药市场预计将达到 11 亿美元。这种严格的监管增强了消费者信心，推动了市场成长。此外，糖尿病发病率的飙昇在这一市场扩张中发挥关键作用。加拿大公共卫生局的数据显示，2021 年，约 9.4% 的人口（即 370 万人）被诊断为糖尿病，其中男性盛行率为 10%，女性盛行率为 8.7%。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 心血管疾病盛行率上升
    • 人们对健康益处的认识不断增强
    • 研究与开发的进步
    • 老年人口不断增加
  • 产业陷阱与挑战
    • 与 omega-3 药物相关的高成本
    • 潜在的副作用
• 成长潜力分析
• 监管环境
• 技术景观
  • 核心技术
  • 邻近技术
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

• 主要趋势
• 瓦塞帕
• 洛瓦札
• 其他药物类型

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 心血管疾病
• 糖尿病
• 神经系统疾病
• 其他应用

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AstraZeneca plc
• Amarin Corporation plc
• Camber Pharmaceuticals, Inc.
• Dr. Reddy's Laboratories Ltd.
• GSK plc
• Grupo Ferrer Internacional, S.A.
• Hikma Pharmaceuticals PLC
• Natco Pharma Limited
• Pfizer Inc.
• Viatris Inc.
• Zydus Lifesciences Limited

The Global Omega-3 Prescription Drugs Market was valued at approximately USD 1.4 billion. Projections indicate a growth rate of 8.2% CAGR from 2024 to 2032. These drugs, formulated with highly purified omega-3 fatty acids like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are primarily used to treat or manage conditions such as cardiovascular diseases, metabolic disorders, and certain inflammatory or neurological issues.

The market growth is significantly driven by the rising prevalence of cardiovascular diseases. A report from the World Heart Federation (WHF) highlighted that the global deaths from cardiovascular disease (CVD) reached 20.5 million in 2021. CVD topped the list as the leading cause of death worldwide in 2021, with a staggering 80% of these fatalities occurring in low- and middle-income countries (LMICs). Such statistics emphasize the urgent demand for effective treatments, like omega-3 prescription drugs, to manage cardiovascular conditions and enhance global health outcomes.

Research and development (R&D) advancements are amplifying the therapeutic potential of omega-3 prescription drugs and broadening their applications. Innovations in purification and formulation technologies are yielding highly concentrated omega-3 preparations, boasting enhanced bioavailability and efficacy. These advancements aim to harness the full therapeutic benefits of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) while curtailing potential side effects. Furthermore, ongoing research is delving into additional therapeutic avenues for omega-3 prescription drugs, venturing beyond cardiovascular health. Areas of exploration include neurological conditions, metabolic disorders, and inflammatory diseases, with clinical trials evaluating omega-3s for managing Alzheimer's disease, rheumatoid arthritis, and diabetes.

The Global Omega-3 Prescription Drugs Industry is classified based on drug type, application, distribution channel and region.

The market categorizes drug types into vascepa, lovaza, and others. Projections suggest the vascepa segment will hit USD 1.3 billion by 2032. Vascepa, a highly concentrated and refined formulation, boasts pure eicosapentaenoic acid (EPA). This high purity guarantees a potent dose of EPA, free from common contaminants in lesser purified omega-3 supplements, thereby amplifying its effectiveness. Clinical evidence underscores Vascepa's prowess: it's not only effective in curbing elevated triglyceride levels-a primary cardiovascular disease risk factor-but also significantly diminishes the risk of major cardiovascular events, as highlighted in studies like the REDUCE-IT trial.

The U.S. omega-3 prescription drugs market is on track to reach USD 1.1 billion by 2032. The U.S. Food and Drug Administration (FDA) enforces stringent oversight and approval processes for these drugs, ensuring they uphold high safety, efficacy, and quality standards. Such regulatory rigor bolsters consumer confidence, fueling market growth. Additionally, the surging incidence of diabetes plays a pivotal role in this market expansion. Data from the Public Health Agency of Canada reveals that in 2021, about 9.4% of the population-translating to 3.7 million individuals-were diagnosed with diabetes, with male prevalence at 10% and female at 8.7%.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cardiovascular diseases
    • 3.2.1.2 Growing awareness of health benefits
    • 3.2.1.3 Advancements in research and development
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs associated with omega-3 drugs
    • 3.2.2.2 Potential side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Vascepa
• 5.3 Lovaza
• 5.4 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cardiovascular diseases
• 6.3 Diabetes
• 6.4 Neurological disorders
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca plc
• 9.2 Amarin Corporation plc
• 9.3 Camber Pharmaceuticals, Inc.
• 9.4 Dr. Reddy's Laboratories Ltd.
• 9.5 GSK plc
• 9.6 Grupo Ferrer Internacional, S.A.
• 9.7 Hikma Pharmaceuticals PLC
• 9.8 Natco Pharma Limited
• 9.9 Pfizer Inc.
• 9.10 Viatris Inc.
• 9.11 Zydus Lifesciences Limited